The field of positron emission tomography (PET) has expanded dramatically over recent years. In spite of this expansion the large majority of clinical studies are carried out utilizing one radiopharmaceutical—2-fluoro- 2-deoxyglucose. Many research groups are developing novel radiopharmaceuticals. Amajor emphasis is on other agents labeledwith ¹⁸F. Several other positron emitting radionuclides can be prepared in high yields in small biomedical cyclotrons. Some of these have half-lives that make delivery significantly easier than the delivery of ¹⁸F compounds. These radionuclides include: ⁶⁴Cu (half life 12.7 h), ⁷⁶Br (half life 16.2 h), ⁸⁶Y(half life 14.74 h) and ¹²⁴I (half life 4.2 days). The method of production of these and other ‘non-standard’ PET radionuclides will be discussed and themethod of labeling radiopharmaceuticals with these radionuclides described. Several of these radiopharmaceuticals have been studied in animal models as well and a limited number translated to the human situation.